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ABSTRACT 
Background: Incomplete immune reconstitution may occur despite successful antiretroviral 
therapy (ART). Gut-associated lymphoid tissue (GALT) fibrosis may contribute via local CD4+ T 
lymphocyte depletion, intestinal barrier disruption, microbial translocation, and immune activa-
tion. 
Methods: In a cross-sectional analysis, we measured circulating fibrosis biomarker levels on 
cryopreserved plasma from adult HIV-infected (HIV+) SCOPE study participants on suppres-
sive ART who also had fibrosis quantification on recto-sigmoid biopsies. Relationships among 
biomarker levels, clinical and demographic variables, GALT lymphoid aggregate (LA) collagen 
deposition, and LA CD4+ T lymphocyte density were analyzed using simple regression. Biomark-
er levels were also compared to levels in HIV+ viremic SCOPE participants and a convenience 
sample of HIV-uninfected (HIV-) samples. 
Results: HIV+ aviremic participants (n = 39) were 92% male and 41% non-white, with median 
age 48 years, CD4+ T lymphocyte count 277 cells/mm3, and 17 years since HIV diagnosis. Most 
biomarkers were lower in HIV− (n = 36) vs HIV+ aviremic individuals, although CXCL4 lev-
els were higher. HIV+ viremic individuals (N = 18) had higher median TGF-ß3, CIC-C1Q, and 
TIMP-1 (P < 0.05) and lower LOXL2 levels (P = 0.08) than HIV+ aviremic individuals. Only high-
er LOXL2 levels correlated with more GALT collagen deposition (R = 0.44, P = 0.008) and lower 
LA CD4+ T lymphocyte density (R = −0.32, P = 0.05) among aviremic individuals.
Conclusions: Circulating LOXL2 levels may be a noninvasive measure of intestinal fibrosis and 
GALT CD4+ T lymphocyte depletion in treated HIV infection. LOXL2 crosslinks elastin and col-
lagen, and elevated LOXL2 levels occur in pathologic states, making LOXL2 inhibition a potential 
interventional target for intestinal fibrosis and its sequelae.
Keywords: GALT, HIV, fibrosis, immune reconstitution
INTRODUCTION 
Despite control of HIV replication with antiretroviral therapy (ART), long-term failure to restore 
CD4+ T lymphocyte numbers has been reported in HIV-infected (HIV+) individuals [1, 2] Addi-
tionally, poorer immune reconstitution has been associated with the development of non-AIDS 
comorbidities and decreased lifespan among HIV+ persons [3]. The pathophysiology of failure to 
achieve immunologic recovery is not fully understood; however, collagen deposition and fibrosis 
in lymphoid tissues, as observed in gut-associated lymphoid tissue (GALT) during HIV infection, 
may contribute to incomplete immune reconstitution by limiting GALT plasticity and immune 
cell homeostasis [4, 5].
Fibrosis occurs when the normal healing response to local inflammation becomes perturbed, 
resulting in an imbalance between deposition and degradation of the extracellular matrix (ECM) 
[6]. Fibroblasts in tissues produce ECM components such as collagen and hyaluronic acid (HA). 
Anti-fibrotic and pro-fibrotic mediators such as chemokines, cytokines, and growth factors (es-
pecially transforming growth factor [TGF]-β1) [7] direct tissue remodeling. ECM turnover also 
involves the innate and adaptive immune systems through production of inflammatory mediators 
[8]. Over time and in the face of a persistent inflammatory stimulus such as HIV infection, pro-
gressive fibrosis occurs that may ultimately compromise organ function. 
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In this study, we analyzed the relationships between GALT collagen deposition, intestinal lym-
phoid aggregate (LA) CD4+ T lymphocyte density, clinical/demographic variables and media-
tors of fibrosis (TGF-ß1-3), matrix metalloproteinase (MMP)-2 and -9, tissue inhibitor of MMP 
(TIMP)-1, chitinase-3-like protein 1 (CHI-3L1), HA, lysyl oxidase-like 2 (LOXL2), [9, 10] type I 
C-terminal collagen pro-peptide (CICP), circulating immune complexes of complement 1q (CIC 
C1Q), [11] plasminogen activator inhibitor-1 (PAI-1), CXC chemokine ligand 4 (CXCL4), [12] 
and pro-protein convertase subtilisin/kexin type 9 (PCSK9). We hypothesized that circulating lev-
els of these fibrosis biomarkers would be associated with the severity of GALT collagen deposition 
and LA CD4+ T lymphocyte depletion in ART-treated, HIV-1-infected adults. 
PATIENTS AND METHODS
Study Population 
We utilized data and plasma samples from participants enrolled in the Observational Study of 
the Consequences of the Protease Inhibitor Era (SCOPE), a longitudinal cohort of HIV+ and 
HIV-uninfected adults followed in San Francisco, California. A subset of 73 SCOPE participants 
underwent recto-sigmoid biopsies and had stored plasma available for biomarker assessment. For 
this cross-sectional analysis, the primary population was further restricted to the subset of par-
ticipants (n = 39) with HIV-1 RNA < 50 copies/mL. As secondary endpoints, a group of viremic 
(HIV-1 RNA > 50 copies/mL) HIV+ individuals (n = 18) from the SCOPE study and a conve-
nience sample of unmatched HIV-uninfected (HIV−) individuals (n = 36) were used for compari-
son analysis of biomarker values. 
The SCOPE cohort was approved by the University of California-San Francisco (UCSF) Com-
mittee on Human Research. All subjects provided informed consent prior to enrollment, and the 
human experimentation guidelines of UCSF were followed in the conduct of clinical research.
Specimen collection and analysis
Rectal biopsy specimens were stained with Masson trichrome to identify collagen fibers and with 
CD4 antibody, as previously described [13]. Collagen abundance and the CD4+ T lymphocyte 
population were assessed using quantitative image analysis.
Clinical parameters 
Clinical and demographic data and medical and medication history were extracted from the 
SCOPE database. 
Circulating fibrosis biomarkers
Levels of fibrosis biomarkers were measured on EDTA plasma by ELISA or multiplex assay using 
commercially available kits. HA (Echelon Biosciences, Salt Lake City, UT), LOXL2 (R&D Systems, 
Minneapolis, Minnesota), and CICP and CIC C1Q (Quidel, San Diego, CA) were measured by 
ELISA. PAI-1, PCSK9, TGF-ß1-3, MMP-2, MMP-9, TIMP-1, CXCL4, Chi3L1 (all R&D Systems, 
Minneapolis, MN) were measured using Luminex xMAP technology. All analytes except LOXL2 
were measured according to the manufacturers’ instructions. For LOXL2, the ELISA plates were 
coated overnight with capture antibody at room temperature. The plate was blocked with reagent 
diluent 1 (R&D Systems, Minneapolis, MN) for 1 hour and washed. Plasma was diluted 1:10 in 
PBS-Tween 10 and added to the plate. After incubating for 2 hours at 37° C and washing, detec-
Pathogens and Immunity - Vol 2, No 2
www.PaiJournal.com
242
tion antibody was added for 2 hours at 37° C. The plate was washed, streptavidin was added and 
the plate was incubated for 20 minutes at room temperature. After washing, TMB was added (Sig-
ma-Aldrich Corp., St. Louis, MO), the plate was incubated for 20 minutes at room temperature, 
and sulfuric acid was added to stop the reaction. The plate was read at 450 nm.
Statistical methods
Continuous variables are presented as medians and interquartile ranges (IQR), and nominal data 
are described as absolute values or percentages. Statistical analyses were performed using the 
Mann-Whitney U-test. Associations were assessed using simple regression and Spearman cor-
relation coefficients. Significance was defined as two-sided α ≤ 0.05. All analyses were exploratory, 
without adjustment for multiple testing.
RESULTS
Study population 
Among the 39 ART-treated, aviremic HIV+ individuals with recto-sigmoid biopsy data and avail-
able plasma for biomarker analysis, 92% were male. Median (IQR) age was 48 (45-55) years, nadir 
CD4+ T lymphocyte count cells was 66 (18-108) cells/mm3, and current CD4+ T lymphocyte cell 
count was 277 (177-483) cells/mm3 (Table 1). Characteristics of viremic HIV+ individuals (n = 18, 
9 ART treated and 9 untreated) were as follows (median, IQR): age 46 (42-52); time since HIV 
diagnosis 15 years (6-20); nadir CD4+ T lymphocyte count 220 cells/mm3 (58-511); plasma HIV-1 
RNA 13,040 copies/mL (4,890-22,524); and current CD4+ T lymphocyte count 291 cells/mm3 
(242-555). Between viremic and aviremic participants, the only significant (P < 0.05) difference in 
clinical and demographic factors was for nadir CD4+ T lymphocyte count, which was higher in 
the viremic group. No demographic or clinical characteristics were available on HIV-uninfected 
participants. 
Table 1: Clinical characteristics of studied population.
N = 39
Male sex 92 (36)
Age (years) 48 (45-55)
White race 59 (23)
Time from HIV diagnosis (years) 17 (15-21)
HBV* co-infection 7 (3)
HCV** co-infection 26 (10)
Nadir CD4+ T lymphocyte count (cells/mm3) 66 (18-108)
pVL (copies/ml)  < 40 
Current CD4+ T lymphocyte count (cells/mm3) 277 (177-483)
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Current CD4+ T lymphocyte percentage 17 (14-26)
Current CD4+:CD8+ T lymphocyte ratio 0.4 (0.2-0.5)
AST (UI/L) 32.5 (26.0-45.0)
ALT (UI/L) 36.5 (24.0-54.0)
BMI (kg/m2) 25.7 (23.7-27.6)
PI-containing ART regimen 64 (25)
Data are expressed in % (number) of subjects or median value (interquartile range, IQR). 
*Hepatitis B virus (HBV) co-infection defined by positive HBV surface antigen 
**Hepatitis C virus (HCV) co-infection defined by positive HCV RNA 
AST: aspartate aminotransferase; ALT: alanine transaminase; PI: protease inhibitor
Collagen deposition and LA CD4+ T lymphocyte populations
Collagen was identified in all GALT biopsy specimens. Median percent LA collagen deposition 
was 10% (8-13). Proportion of LA CD4+ T lymphocytes was 19% (14-24), and frequency sig-
nificantly negatively correlated with percent LA collagen deposition (r = −0.44, P = 0.007 simple 
regression; r = −0.39, P = 0.02, Spearman) (Figure 1). No significant correlations were found be-
tween collagen deposition and circulating biomarkers of immune status.
Figure 1. Lymphoid aggregate (LA) fibrosis and CD4+ T lymphocyte frequency.  
Figure legends:  
X axis: percentage of lymphoid aggregate collagen deposition (%) 
Y axis: proportion of CD4 lymphoid aggregate (%)
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Intestinal collagen deposition and circulating fibrosis biomarkers
Levels of circulating fibrosis biomarkers are summarized in Table 2. LOXL2 levels demonstrated a 
significant relationship with collagen deposition and LA CD4+ T lymphocyte counts. Specifically, 
LOXL2 positively correlated with LA collagen deposition (r = 0.44, P = 0.008, simple regression; 
r = 0.33, P = 0.09, Spearman) (Figure 2(a)), and negatively correlated with LA CD4+ T lymphocyte 
counts (r = −0.32, P = 0.05, simple regression; r = −0.11, P = 0.20 Spearman) (Figure 2(b)).
Figure 2. Circulating LOXL2 level correlates with (a) lymphoid aggregate (LA) collagen deposition and (b) 
CD4+ lymphoid agregate. 
Figure legends 2a: 
X axis: percentage of lymphoid aggregate collagen deposition (%)  
Y axis: level of LOXL2 (ng/mL)
Figure legends 2b: 
X axis: proportion of CD4 lymphoid aggregate (%)  
Y axis: level of LOXL2 (ng/mL)
In additional exploratory analyses, no significant differences in fibrosis biomarker levels were 
found by success or failure of circulating CD4+ T lymphocyte recovery, with the exception of 
significantly higher MMP-2 levels and MMP-2:TIMP-1 ratios among HIV+, aviremic individuals 
with CD4+ T lymphocyte counts < 350 cells/mm3 compared to those with > 350 cells/mm3 (Ta-
ble 2). Finally, longer duration of HIV infection correlated with higher TIMP-1 levels (r = 0.35, 
P = 0.03), and lower CXCL4 and CIC C1Q levels (simple regression r = −0.35, P = 0.03; r = −0.32, 
P = 0.04, respectively). 
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Table 2: Circulating fibrosis biomarker levels among HIV+ aviremic individuals and by im-
mune reconstitution status.*
*Values are expressed as median (interquartile range, IQR) 
**P value for Mann-Whitney test comparing group 1 vs group 2 
TGF = transforming growth factor, MMP = matrix metalloproteinase, TIMP = tissue inhibitor of MMP, 
CHI-3L1 = chitinase-3-like protein 1, HA = hyaluronic acid, LOXL2 = lysyl oxidase-like 2, CICP = type I 
C-terminal collagen pro-peptide, CIC C1Q = circulating immune complexes of complement 1q, PAI = plas-
minogen activator inhibitor, CXCL4 = CXC chemokine ligand 4 
Biomarker level comparisons between HIV+ aviremic, HIV+ viremic and HIV- participants
Fibrosis biomarkers were also compared between viremic and aviremic participants (Table 3). 
Results showed significantly higher TGF-ß3, CIC C1Q, and TIMP-1 levels among HIV+ viremic 
individuals, with a trend for lower LOXL2 level (0.2 ng/mL [0.2-0.2] vs 0.2 ng/mL [0.2-11.6], 
P = 0.08). When comparing HIV+ aviremic to HIV−individuals, TGF-ß2, matrix metalloprotein-
ase-2, TIMP-1, Chi3L1, hyaluronic acid, CICP, and CIC C1Q were significantly lower (P < 0.05) in 
HIV− individuals, while CXCL4 levels were higher in HIV− individuals (Table 3). 
Overall
(N = 39)
GROUP 1: 
CD4+ T lymphocyte count 
< 350 cells/mm3
(N = 27)
GROUP 2:
CD4+ T lymphocyte count 
≥350 cells/mm3
(N = 12)
P val-
ue**
TGF-ß1 (pg/mL) 12,699 (6,421-17,930) 15,336 (5,661-20,719) 12,316 (9,787-14,038) 0.83
TGF-ß2 (pg/mL) 996 (839-1,124) 993 (709-1,085) 1,099 (937-1,146) 0.11
TGF-ß3 (pg/mL) 300 (150-404) 255 (99-365) 351 (215-410) 0.17
MMP-2 (pg/mL) 151,129 (124,433-203,864) 179,776 (134,654-258,128) 121,898 (105,718-143,495) 0.004
MMP-2 TIMP-1 ratio 4.2 (3.5-6.8) 4.7 (3.5-6.8) 3.2 (2.3-4.7) 0.04
MMP-9 (pg/mL) 7,823 (5,034-12,473) 6,878 (4,814-11,054) 7,984 (7,081-16,910) 0.20
MMP-9 TIMP-1 ratio 0.20 (0.13-0.40) 0.19 (0.11-0.37) 0.33 (0.16-0.41) 0.25
TIMP-1 (pg/mL) 42,589 (37,567-47,792) 42,340 (37,567-47,912) 42,780 (38,850-45,310) 0.95
CHI-3L1 (pg/mL) 42,900 (26,144-66,183) 39,939 (24,215-64,226) 50,330 (28,614-75,949) 0.42
HA (ng/mL) 47.0 (35.0-86.6) 48.5 (28.3-88.6) 46.0 (36.9-82.6) 0.86
LOXL2 (ng/mL) 0.2 (0.2-11.6) 0.2 (0.2-11.0) 2.1 (0.2-13.7) 0.16
CICP (ng/mL) 105.6 (84.6-148.6) 110.5 (90.4-159.6) 98.1 (62.2-146.3) 0.39
CIC C1Q (µg Eq/mL) 147.4 (95.7-199.9) 128.9 (95.7-193.0) 177.2 (91.4-233.1) 0.63
PAI-1 (pg/mL) 32,239 (17,623-45,084) 32,239 (13,741-47,196) 30,706 (25,244- 40,171) 0.93
CXCL4 (pg/mL) 1,561,900 
(401,723-2,845,850)
1,232,500 
(250,399-2,734,050)
2,347,450
(1.691,050-2,790,800)
0.12
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Table 3: Circulating fibrosis biomarker levels overall among HIV infected and HIV uninfect-
ed individuals*
*Values are expressed as median (interquartile range, IQR) 
**P value for Mann-Whitney test comparing HIV+ aviremic group vs HIV+ viremic group 
***P value for Mann-Whitney test comparing HIV+ aviremic group vs HIV negative group 
pVL = plasma viral load, TGF = transforming growth factor, MMP = matrix metalloproteinase, TIMP = tis-
sue inhibitor of MMP, CHI-3L1 = chitinase-3-like protein 1, HA = hyaluronic acid, LOXL2 = lysyl oxi-
dase-like 2, CICP = type I C-terminal collagen pro-peptide, CIC C1Q = circulating immune complexes of 
complement 1q, PAI = plasminogen activator inhibitor, CXCL4 = CXC chemokine ligand 4 
DISCUSSION
In this group of HIV+ aviremic individuals on suppressive ART, GALT fibrosis was universally 
present, with more fibrosis associated with lower CD4+ T lymphocyte percentage in LA. Addition-
ally, we found significant correlations among GALT collagen deposition, LA CD4+ T lymphocyte 
frequency, and circulating LOXL2 levels.
HIV+ AVIREMIC group
(HIV-1 pVL < 50cp/mL)
(N = 39)
HIV+ VIREMIC 
group 
(HIV-1 pVL > 50cp/
mL)
(N = 18)
P ** HIV negative group 
 (N = 36)
P ***
TGF-ß1 (pg/mL) 12,699 (6,421-17,930) 14,890 (10,792-
17,696)
0.44 9,746 (7,104-16,880) 0.34
TGF-ß2 (pg/mL) 996 (839-1,124) 1,084 (963-1,135) 0.19 836 (729-946) 0.005
TGF-ß3 (pg/mL) 300 (150-404) 377 (331-418) 0.03 252 (151-467) 0.87
MMP-2 (pg/mL) 151,129 (124,433-203,864) 149,560 (120,202-
178,693)
0.49 60,028 (60,028-
76,312)
 < 0.0001
MMP-2 TIMP-1 ratio 4.2 (3.5-6.8) 3.0 (2.4-4.2) 0.04 3.2 (2.7-4.9) 0.09
MMP-9 (pg/mL) 7,823 (5,034-12,473) 6,232 (4,640-8,936) 0.11 9,108 (4,006-16,544) 0.89
MMP-9 TIMP-1 ratio 0.2 (0.13-0.40) 0.1 (0.1-0.2) 0.02 0.46 (0.15-1.1) 0.02
TIMP-1 (pg/mL) 42,589 (37,567-47,792) 47,947 (44,130-
50,164)
0.03 19,099 (16,714-
21,418)
 < 0.0001
CHI-3L1 (pg/mL) 42,900 (26,144-66,183) 39,379 (20,117-
71,586)
0.62 17,100 (12,231-
27,442)
 < 0.0001
HA (ng/mL) 47.0 (35.0-86.6) 60.1 (40.1-67.4) 0.77 32.4 (21.2-49.8) 0.01
LOXL2 (ng/mL) 0.2 (0.2-11.6) 0.2 (0.2-0.2) 0.08 4.9 (0.2-23.2) 0.15
CICP (ng/mL) 105.6 (84.6-148.6) 105.1 (85.2-116.6) 0.66 72 (56-92)  < 0.0001
CIC C1Q (µg Eq/mL) 147.4 (95.7-199.9) 234 (125-350) 0.01 5.2 (3.4-7.8)  < 0.0001
PAI-1 (pg/mL) 32,239 (17,623-45,084) 35,319 (23,692-
59,571)
0.22 26, 952 (16,815-
72,171)
0.98
CXCL4 (pg/mL) 1,561,900 
(401,723-2,845,850)
2,400,950 
(876,244-3,735,200)
0.10 3,296,800 (2,312,900-
5,337,600)
 < 0.0001
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HIV+ individuals may display an incomplete immune restoration despite control of HIV rep-
lication. Interestingly, all participants had a long history of HIV infection and our sample was 
enriched for those who persistently had CD4+ T lymphocyte counts < 350 cells/mm3 (69%). This 
population can therefore be considered to consist primarily of immunologic non-responders (me-
dian CD4+ T lymphocyte count 277 cells/mm3), and the lack of peripheral immune restoration 
may partially result from alterations of intestinal immunity. In the first weeks of HIV infection, 
gut mucosal CD4+ T lymphocyte depletion occurs and, with disruption of the mucosal barrier, 
permits increased microbial translocation. Over time, this leads to chronic stimulation of the 
adaptive and innate immune systems, perpetuating gut damage, local HIV replication, and CD4+ 
T lymphocyte depletion, culminating in fibrosis [14, [15]. Simultaneously, the lymphatic tissue is 
affected by structural remodeling, from hyperplasia to follicular involution [16, 17] and/or fibro-
sis [13]. In this virologically suppressed population, we reported a high level of collagen deposi-
tion in all biopsy samples and a negative correlation between LA CD4+ T lymphocyte frequency 
and LA collagen deposition, consistent with previously described results from the complete 
SCOPE biopsy population [13]. These findings support GALT fibrosis as a contributor to incom-
plete CD4+ T lymphocyte cell restoration in chronic HIV infection despite suppressive ART [13, 
14].
This study is the first to explore the relationship between gut collagen deposition and circulat-
ing fibrosis biomarkers among HIV+ individuals on suppressive ART. Interestingly, we found 
that LOXL2 levels increase with LA collagen deposition and are inversely correlated with CD4+ 
T lymphocyte frequency in LA. LOXL2 is a metalloenzyme that plays an important role in the 
progression of fibrotic disease by promoting collagen and elastin cross-linkage, which is essen-
tial for the tensile strength of the ECM [18]. Interestingly, while LOXL2 plays an essential role in 
angiogenesis, wound healing, and scar formation, [19, 20] it is not thought to be over-expressed 
in normal hosts [9, 21] and its upregulation has been associated with the development of fibrotic, 
hematologic, and malignant diseases [9, 10, 19, 21-25]. 
Thus, our findings suggest a dynamic GALT remodeling process that may prevent complete im-
mune restoration on ART. This hypothesis is supported by the fact that we also observed a strong 
positive relationship between duration of HIV infection and TIMP-1 levels, suggesting chronic 
and potentially escalating tissue remodeling [26]. We also observed significantly higher MMP-
2 levels and MMP-2:TIMP-1 ratios in HIV+ individuals with CD4+ T lymphocyte counts < 350 
cells/mm3, indicative of ongoing ECM remodeling [27]. While high MMP-2 and TIMP-1 levels 
have been associated with severity of liver fibrosis, [28, 29] in this cohort levels did not differ by 
viral hepatitis co-infection status (data not shown).While we did not observe an association be-
tween circulating LOXL2 levels and circulating CD4+ T lymphocyte counts, the circulating CD4+ 
cells pool is derived from a number of tissues that may not be affected/equally affected by fibrosis, 
preventing a strong correlation. 
In an exploratory subanalysis, comparison of fibrosis biomarker levels between aviremic and 
viremic HIV+ individuals demonstrated a trend toward lower LOXL2 levels in the viremic group. 
This result could be explained by the significantly higher nadir CD4+ T lymphocyte values among 
viremic HIV+ individuals, reflecting less immunologic damage and, potentially, lower inflamma-
tion and fibrosis in this group. Additionally, most fibrosis biomarkers were significantly lower in 
HIV− group compared to the HIV+ aviremic group, as expected. While CXCL4 levels were high-
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er among HIV− persons, this was also expected: we previously demonstrated among Multicenter 
AIDS Cohort participants that CXCL4 levels are lower among persons with failure to immune 
reconstitute on ART, [30] and in vitro data suggest that lower CXCL4 levels in HIV+ persons may 
be a marker of successful immune evasion by the virus [31]. Thus, persons with lower CXCL4 
levels on suppressive ART may be reflective of greater immunologic devastation. Additionally, 
CXCL4 originates from activated platelets, and circulating levels are elevated in atherosclerosis 
and cardiovascular disease, [32, 33] malignancy, [34-36] and systemic sclerosis [12, 37]. Thus, 
many factors affect CXCL4 levels.
Finally, no significant difference in LOXL2 levels was observed between HIV− and HIV+ avi-
remic participants, which is not surprising as, given that LOXL2 upregulation is associated with 
pathologic states, levels are low in most persons. Notably, the HIV− group was a sample of stored 
plasma from unmatched HIV− individuals with unknown medical histories and no GALT biop-
sy data, so this finding must be interpreted with caution. Additionally, circulating LOXL2 levels 
have not been measured in many clinical cohorts, so the effect of factors such as age, sex, obesity, 
cardiovascular disease, and liver disease on LOXL2 levels are unknown. Thus, we believe that the 
lack of statistical difference in levels between HIV+ aviremic persons and unmatched HIV− per-
sons does not take away from the strong relationship observe between circulating LOXL2 levels 
and the extent of GALT fibrosis and CD4+ T lymphocyte depletion observed in HIV+ aviremic 
adults.
Our study has several limitations: The cross-sectional design and small sample size may have pre-
vented us from observing additional statistically significant relationships between other circulat-
ing fibrosis biomarkers and GALT collagen deposition, particularly for markers that may fluctuate 
more widely within individuals and/or have higher coefficients of variation. Additionally, we were 
not powered to look at gender differences in the observed relationships, as the vast majority of 
participants with available samples were males. The majority of our participants also identified 
as being of white race. Thus, our results cannot be generalized to women and/or the global HIV+ 
population. Finally, HIV− control samples came from an unmatched convenience sample of per-
sons without clinical profiling. 
In conclusion, LOXL2 levels increase with GALT lymphoid aggregate collagen deposition and are 
inversely correlated with lymphoid aggregate CD4+ T lymphocyte frequency in HIV+ adults on 
suppressive ART. Further studies are needed to assess the utility of circulating LOXL2 as a non-
invasive marker of fibrotic tissue burden in treated HIV infection. Finally, specific inhibitors of 
LOXL2 should be explored for the prevention and treatment of fibrotic disease in chronic HIV 
infection.
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